Sino Biological has developed three neutralizing antibodies against SARS-CoV-2. The activities of these antibodies have been extensively validated in both binding assays, and pseudovirus infection assays. These reagents can be used as reference antibodies in neutralization assays, and possibly animal studies as well.
SARS-CoV-2 keeps evolving by continual mutation which enable the virus to evade vaccines and immune systems. Some of the mutations ,the U.K. variant B.1.1.7, the Brazil variant P.1, the South Africa variant B.1.351 and the Indian variant B.1.617, may have allowed the virus to escape from neutralizing antibodies. To characterize these variants, a new panel of monoclonal antibodies have been launched. These antibodies demonstrate differential neutralizing activities against different variants validated by Competitive ELISA Assay. Notably, the B.1.351 and P.1 variants seem to be immune to a subset of the antibodies.
|Neutralizing Antibodies||WT RBD||Recombinant RBD||Recombinant S1|
The microneutralization assay was performed on 293T-ACE2 cells infected with SARS-CoV-2 Spike PSV. Neutralizing antibodies can effectively inhibit the infection of SARS-CoV-2 Spike pseudovirus on ACE2 overexpression 293T cells.
Neutralizing ability was detected by SARS-CoV-2 Inhibitor Screening ELISA Kit (Catalog# KIT001) using competitive ELISA.
SARS-CoV-2 shares 80% sequence identity to the 2003 SARS-CoV. Hence, antibodies raised against SARS-CoV-2 antigens often shows various degree of cross-reactivity with the corresponding antigens of 2003 SARS-CoV. On the other hand, the similarities between SARS-CoV-2 and other members of human coronavirus are very limited. The following two clones of anti-spike antibodies have been tested against all seven coronavirus, and are shown to be specific to SARS-CoV-2 spike.
The binding between immobilized SARS-CoV-2 RBD protein (40592-V08B-B) and the anti-Spike antibody 40592-R001 in Octet RED assay.